F-18 FDG PET/CT in the Diagnosis of a Rare Case of Neurosarcoidosis in a Patient With Diabetes Insipidus

Asabella, Artor Niccoli; Gatti, Pietro; Notaristefano, Antonio; Iuele, Francesca; Altini, Corinna; Rubini, Giuseppe

doi:10.1097/rlu.0b013e318219b28b

Cited by 6 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients included 12 men [8-12, 14, 15, 17] and eight women [7,10,13,16,18,19], with a mean age of 33 years. The first symptom was polyuria in 13 patients [7][8][9][11][12][13][14][15][16][17] and polydipsia in eight patients [7][8][9][11][12][13][14][15]. The mean duration from disease onset to diagnosis was 3.4 months.…”

Section: Study Selectionmentioning

confidence: 99%

“…Brain MRI showed abnormal findings in the pituitary stalk in 10 patients [7,8,[10][11][12][13]16], abnormal findings in the pituitary gland in nine patients [8][9][10][11][12][13]15], and loss of high intensity of the posterior lobe of the pituitary in nine patients [8,9,[11][12][13]. Twelve patients were diagnosed through biopsies of the lymph nodes [8,10,14,16,17], lungs [8][9][10], and skin [13,15], while only one patient underwent a brain biopsy [8]. Table III provides a detailed list of the clinical treatments, brain MRI findings, and outcomes of patients with neurosarcoidosis and CDI.…”

Section: Study Selectionmentioning

confidence: 99%

“…Steroid therapy was administered to 17 patients [8][9][10][11][12][14][15][16][17][18][19], infliximab was administered to two patients [17,19], cyclophosphamide was administered to one patient [10], and methotrexate was administered to one patient [19]. Desmopressin (1-desamino-8-D-arginine vasopressin) (DDAVP) was used to treat the symptoms of CDI in 19 patients [7][8][9][10][11][12][13][14][16][17][18][19]. Fourteen patients showed improvement in their abnormal brain MRI findings [8][9][10][11][12][13][15][16][17], but no patients showed improvement in the loss of high signal intensity in the posterior lobe of the pituitary.…”

Section: Study Selectionmentioning

confidence: 99%

“…; F -female; GI -gastrointestinal; LN -lymph node; TBLB -transbronchial lung biopsy; PRL -prolactin; LH -luteinising hormone; FSH -follicle-stimulating hormone; ACTH -adrenocorticotropic hormone; TSH -thyroid stimulating hormone; GH -growth hormone; MRI -magnetic resonance imagingREVIEW Table III. Clinical treatments, brain magnetic resonance imaging findings, and outcomes of patients with neurosarcoidosis and central diabetes insipidus in good remission of the pituitary and abdominalmanifestations measured radiologically, although hypogonadism persisted ophthalmologic sarcoidosis, pulmonary lesions, and cutaneous sarcoidosis remained unchanged throughout the clinical course8 Alam et al[14] …”

mentioning

confidence: 99%

See 3 more Smart Citations

Magnetic resonance imaging and symptoms in patients with neurosarcoidosis and central diabetes insipidus

Kakehi¹,

Adachi²,

Fukuyasu³

et al. 2019

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: In the clinical setting, the diagnosis of neurosarcoidosis in patients with central diabetes insipidus (CDI) is typically based both on symptoms (i.e. polydipsia or polyuria) and brain magnetic resonance imaging (MRI) findings (e.g. pituitary abnormality). However, inconsistent changes in the patient's symptoms and brain MRI findings may occur during the clinical course of the disease. This review was performed to summarise the relationship between symptoms and brain MRI findings in previously reported cases of neurosarcoidosis with CDI. Material and methods: Case studies of patients diagnosed with neurosarcoidosis with CDI were collected via a PubMed search of studies published through 30 June 2018. Results: Thirteen eligible studies were reviewed (20 patients; 12 men, 8 women; mean age 33 years). Polydipsia or polyuria was the first symptom in 13 patients. The mean duration from disease onset to diagnosis was 3.4 months. Brain MRIs showed abnormal findings in the hypothalamus and pituitary for 17 patients. Immunosuppressive drugs were used in 17 patients. For 14 patients, MRI findings improved, while symptoms did not. Conclusion: Patients with both neurosarcoidosis and CDI symptoms often do not improve, despite the fact that brain MRI findings often improve following treatment. More studies involving detailed pathological analyses and longer follow-up periods are necessary.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Magnetic resonance imaging and symptoms in patients with neurosarcoidosis and central diabetes insipidus

Kakehi¹,

Adachi²,

Fukuyasu³

et al. 2019

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

Radio-guided sentinel lymph node identification by lymphoscintigraphy fused with an anatomical vector profile: clinical applications

et al. 2013

View full text Add to dashboard Cite

We have created a new, practical, inexpensive digital technique based on commercial software for fusing lymphoscintigraphic images with built-in anatomical reference profiles. It is easily reproducible and does not alter the original scintigraphic image. Our method allows a more meaningful interpretation of lymphoscintigraphies, an easier recognition of the anatomical site and better lymph node dissection planning.

show abstract

18F-FDG Uptake in Neurosarcoid Dural Plaque on PET/CT

Khodarahmi

Turbin²,

Frohman³

et al. 2016

Clinical Nuclear Medicine

View full text Add to dashboard Cite

While the imaging modality of choice to diagnose neurosarcoidosis is gadolinium-enhanced MRI, F-FDG PET/CT maybe used to stage the disease or target the optimal biopsy site. Few cases have described intense F-FDG uptake at the sites of active neurosarcoidosis in the midbrain and pituitary gland, cerebellar hemispheres, and temporal lobes. Here, we present a case of neurosarcoidosis whose PET/CT examination demonstrated F-FDG avidity in a dural plaque.

show abstract

F-18 FDG PET/CT in the Diagnosis of a Rare Case of Neurosarcoidosis in a Patient With Diabetes Insipidus

Cited by 6 publications

References 8 publications

Magnetic resonance imaging and symptoms in patients with neurosarcoidosis and central diabetes insipidus

Magnetic resonance imaging and symptoms in patients with neurosarcoidosis and central diabetes insipidus

Radio-guided sentinel lymph node identification by lymphoscintigraphy fused with an anatomical vector profile: clinical applications

18F-FDG Uptake in Neurosarcoid Dural Plaque on PET/CT

Contact Info

Product

Resources

About